The Retinol Binding Protein-4 (RBP4) Gene and Gestational Diabetes

Saucedo, Renata; Valencia, Jorge; Basurto, Lourdes; Hernández, Marcelino; Puello, Edgardo; Zárate, Arturo; Mendoza, Patricia; Ostrosky, Patricia

doi:10.1007/978-3-319-56440-1_12

Cited by 2 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the cross-sectional nature of the study design cannot be translated into a clear cause-effect inference. Third, several genetic variants that affect RBP4 expression levels (e.g., rs3758539 and rs12265684) have been investigated for their potential association with the risk of GDM, but the reported findings are inconsistent [21,42]. The information about RBP4 genetic variants were not obtained.…”

Section: Discussionmentioning

confidence: 99%

A Prospective Study of Maternal Plasma Concentrations of Retinol-Binding Protein 4 and Risk of Gestational Diabetes Mellitus

Du¹,

Kong²

2018

Ann Nutr Metab

View full text Add to dashboard Cite

Background: The aim of this study was to investigate whether retinol-binding protein 4 (RBP4) concentrations, measured at the first prenatal visit, are associated with risk of gestational diabetes mellitus (GDM). Methods: From July 2015 to June 2016, consecutive women who admitted to the obstetrics center of our hospital were included. At the first prenatal visit (the median gestational age was 6 [interquartile range 4–10] weeks) in the hospital, involved subjects were tested for fasting plasma glucose (FPG) and RBP4 using venous plasma samples collected after at least 8 h of fasting in the morning. Data for FPG and RBP4 concentrations at the first prenatal visit and one-step GDM screening with 75-g oral glucose tolerance test performed between 24 and 28 weeks of gestation were collected and analyzed. Results: Blood at first prenatal visit was available for 827 women, among whom GDM developed in 101 (12.2%). In multivariate models comparing the second (Q2), third, and fourth quartiles against the first quartile of RBP4, concentrations of RBP4 in Q2, Q3, and Q4 were associated with GDM later developed, and increased risk of GDM by 54, 205, and 536%. There was a significant statistical difference in the area under the curve between the established risk factors alone and the addition of RBP4 concentrations (difference, 0.039 [95% CI 0.030–0.052]; p = 0.03). In the subgroup of women combined with obesity and FABP4 ≥median, the measured OR was 9.83 (95% CI [4.76–16.13]; p < 0.001) for GDM compared to those without obesity and FABP4

show abstract

Section: Discussionmentioning

confidence: 99%

A Prospective Study of Maternal Plasma Concentrations of Retinol-Binding Protein 4 and Risk of Gestational Diabetes Mellitus

Du¹,

Kong²

2018

Ann Nutr Metab

View full text Add to dashboard Cite

show abstract

“…A 2005 study showed for the first time the potential involvement of RBP4 in the pathogenesis of type 2 diabetes ( 11 ), with the expression of RBP4 playing a regulatory role in glucose metabolism in both the liver and skeletal muscle. Indeed, the decreased expression of glucose transporter-4 (GLUT4) is linked to increased RBP4 secretion from the adipose tissue, which leads to increased hepatic gluconeogenesis and reduced glucose uptake in the muscle, ultimately resulting in increased blood glucose levels, impaired glucose tolerance, and diabetes ( 12 ). Furthermore, recent studies have also revealed close associations between RBP4 and cardiovascular disease (CVD) and related risk factors, such as obesity, hypertension, dyslipidemia, heart failure, and coronary heart disease ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

Retinol-binding protein 4 (RBP4) circulating levels and gestational diabetes mellitus: a systematic review and meta-analysis

Leca,

Kite,

Lagojda

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundGestational diabetes mellitus (GDM) is a prevalent condition where diabetes is diagnosed during pregnancy, affecting both maternal and fetal outcomes. Retinol-binding protein 4 (RBP4) is a circulating adipokine which belongs to the lipocalin family and acts as a specific carrier protein that delivers retinol (vitamin A) from the liver to the peripheral tissues. Growing data indicate that circulating RBP4 levels may positively correlate with GDM. Thus, this systematic review and meta-analysis aimed to investigate the potential relationship between circulating RBP4 levels and GDM when measured at various stages of pregnancy.MethodsMEDLINE, CINAHL, EMCARE, EMBASE, Scopus, and Web of Science databases were searched to identify studies comparing pregnant women with and without GDM, whose circulating RBP4 levels were measured in at least one pregnancy trimester. Findings were reported using standardized mean difference (SMD) and random-effects models were used to account for variability among studies. Furthermore, the risk of bias was assessed using the RoBANS tool.ResultsOut of the 34 studies identified, 32 were included in the meta-analysis (seven with circulating RBP4 levels measured in the first trimester, 19 at 24–28 weeks, and 14 at >28 weeks of pregnancy). RBP4 levels were statistically higher in the GDM group than in controls when measured during all these pregnancy stages, with the noted RBP4 SMD being 0.322 in the first trimester (95% CI: 0.126–0.517; p < 0.001; 946 GDM cases vs. 1701 non-GDM controls); 0.628 at 24–28 weeks of gestation (95% CI: 0.290–0.966; p < 0.001; 1776 GDM cases vs. 1942 controls); and 0.875 at >28 weeks of gestation (95% CI: 0.252–1.498; p = 0.006; 870 GDM cases vs. 1942 non-GDM controls). Significant study heterogeneity was noted for all three pregnancy timepoints.ConclusionThe present findings indicate consistently higher circulating RBP4 levels in GDM cases compared to non-GDM controls, suggesting the potential relevance of RBP4 as a biomarker for GDM. However, the documented substantial study heterogeneity, alongside imprecision in effect estimates, underscores the need for further research and standardization of measurement methods to elucidate whether RBP4 can be utilized in clinical practice as a potential GDM biomarker.Systematic review registrationPROSPERO (CRD42022340097: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022340097).

show abstract

The Retinol Binding Protein-4 (RBP4) Gene and Gestational Diabetes

Cited by 2 publications

References 48 publications

A Prospective Study of Maternal Plasma Concentrations of Retinol-Binding Protein 4 and Risk of Gestational Diabetes Mellitus

A Prospective Study of Maternal Plasma Concentrations of Retinol-Binding Protein 4 and Risk of Gestational Diabetes Mellitus

Retinol-binding protein 4 (RBP4) circulating levels and gestational diabetes mellitus: a systematic review and meta-analysis

Contact Info

Product

Resources

About